Author + information
Cyclophilin A (CyPA) is a secreted protein and involved in the pathogenesis of various cardiovascular diseases. However, the association between CyPA and pulmonary hypertension is still unknown. In this study, we aimed to investigate the role of CyPA in the progression of pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD).
This study included healthy control group (n=45), pure COPD group (n=59) and COPD with pulmonary hypertension group (n=53). The three groups were well matched for age, gender, body mass index and smoking index. Basic clinical information was collected, and then all participants underwent pulmonary function testing and transthoracic echocardiography. Serum concentrations of CyPA, matrix metalloproteinase 9 (MMP-9) and C-reactive protein (CRP) were measured by enzyme linked immunosorbent assay.
Compared with the healthy control group, pulmonary function was significantly decreased in COPD patients with or without pulmonary hypertension (P<0.05). And pulmonary function in the COPD with pulmonary hypertension group was worse than that in the pure COPD group (P<0.05). The serum level of CyPA was significantly higher in the pure COPD group than that in the healthy control group (P<0.05), and further increased in the COPD with pulmonary hypertension group (P<0.05). Spearman rank correlation analysis demonstrated that serum CyPA had positive correlations with serum MMP-9 and CRP in the COPD with pulmonary hypertension group (r=0.452 and 0.538, both P<0.01). Furthermore, serum CyPA correlated positively with pulmonary artery systolic pressure in the COPD with pulmonary hypertension group (r=0.572 P<0.01).
Serum CyPA may be a valuable marker for predicting the severity of pulmonary hypertension secondary to COPD.